MissionIR would like to highlight VistaGen Therapeutics, Inc. (http://www.missionir.com/market-research.html">OTCBB: VSTA), a biotechnology company, focused on applying proprietary human pluripotent stem cell technology for drug rescue and cell therapy. Its Human Clinical Trials in a Test Tube is a pluripotent stem cell technology platform for predictive toxicology, drug development, and drug rescue.
In the company’s news yesterday:
A recent article by Ryan McBride in biotech industry newsletter FierceBiotech (http://dtg.fm/i12W) highlights a major transition that needs to occur in the pharmaceutical industry.
The article points to a speech by Ken Kaitin, director of the Tufts Center for the Study of Drug Development, suggesting that drug development companies need to fix broken areas of development that are costing them billions of dollars from unnecessary procedures in clinical trials. Kaitin’s group expects pharma to replace traditional trial-and-error testing methods with newer approaches, such as biomarkers, modeling, and simulation, all in an effort to reduce failures and associated costs, costs which payers are increasingly reluctant to accept.
It’s exactly the issue that is being addressed by VistaGen Therapeutics’ proprietary stem cell technologies. VistaGen is a California-based biotechnology company applying its human pluripotent stem cell technology for drug rescue applications, including predictive toxicology and drug metabolism screening. The company intends to use its proprietary technology to discover, rescue, and develop novel drug candidates for a wide range of diseases.
The company’s platform, Human Clinical Trials in a Test Tube, is based on the differentiation of human pluripotent stem cells into multiple types of mature human heart and liver cells which can then be used to provide clinically relevant predictions of potential toxicity. Determination of toxicity at these early stages, far earlier than standard clinical trials, means that drug candidates have a chance of being modified for a successful outcome, saving tremendous amounts of money.
Many otherwise promising drug candidates have been shelved due to toxicity issues that surfaced well into the development and introduction process, representing major losses for drug companies. It suggests a growing recognition of the incredible value offered by technologies such as those VistaGen represents.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.